Many Anavex Life Sciences Corp.(AVXL) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Anavex Life Sciences Corp. was Initiated by Noble Financial on Feb 7, 2017 to Buy, Price Target of the shares are set at $16.
Company has reported several Insider transactions to the SEC, on Jul 14, 2015, Christopher U Missling (CEO) purchased 1,000 shares at 0.52 per share price.
Anavex Life Sciences Corp. (NASDAQ:AVXL) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1 by 3 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys.
Anavex Life Sciences Corp. (NASDAQ:AVXL) stock has received a short term price target of $ 13.67 from 3 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $3.21. The higher estimate of target price is $16 , while the lower price target estimate is $10
Anavex Life Sciences Corp. (NASDAQ:AVXL) rose 2% or 0.12 points on Tuesday and made its way into the gainers of the day. After trading began at $6.17 the stock was seen hitting $6.3 as a peak level and $5.9 as the lowest level. The stock ended up at $6.13. The daily volume was measured at 966,653 shares. The 52-week high of the share price is $8.3 and the 52-week low is $2.43. The company has a market cap of $252 million.
ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The companys proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill specific criteria based on unmet market needs and new scientific advances. Selected drug candidates demonstrate high, non-exclusive affinity for sigma receptors, which are involved in the modulation of multiple cellular biochemical signaling pathways.